INFLUENCE OF AMPICILLIN/CLOXACILLIN ON THE PHARMACOKINETICS OF CHLORPROPAMIDE IN TYPE II DIABETES MELLITUS PATIENTS
INFLUENCE OF AMPICILLIN/CLOXACILLIN ON THE PHARMACOKINETICS OF CHLORPROPAMIDE IN TYPE II DIABETES MELLITUS PATIENTS
| dc.contributor.author | ISAAC, ENEMALI SHAIBU | |
| dc.date.accessioned | 2014-02-04T15:58:01Z | |
| dc.date.available | 2014-02-04T15:58:01Z | |
| dc.date.issued | 1999 | |
| dc.description | A THESIS SUBMITTED TO THE POSTGRADUATE SCHOOL, AHMADU BELLO UNIVERSITY, ZARIA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF THE DEGREE OF MASTER OF SCIENCE IN PHARMACEUTICAL CHEMISTRY DEPARTMENT OF PHARMACEUTICAL AND MEDICINAL CHEMISTRY , FACULTY OF PHARMACEUTICAL SCIENCES, AHMADU BELLO UNIVERSITY ZARIA, NIGERIA 1999 | en_US |
| dc.description.abstract | Infection is very common in diabetics and its treatment should be prompt. This study is to examine the influence of ampiclox (Ampicillin/Cloxacillin) Capsules on the pharmacokinetics of chlorpropamide tablets in Type II diabetic patients. Seven type II diabetic patients with age ranging from 35-70 yrs, weight ranging from 55-70 kg and height from 1.65 - 1.78m participated in the study. Each patient received the following treatments at two weeks interval: 250mg Chlorpropamide tablet alone and one 250mg Chloropromede table with one 500mg Ampiclox capsule. Blood samples were taken at intervals for 168hours. Plasma Samples were analysed by sp8 - 100 spectrophotometer. The plasma peak concentration (Cmax), the amount of drug absorbed (AUC) and the elimination half - life (t½e[) were all significantly (P<0.05) increased following the second treatment with the lag-time. The statistical analysis was carried out using student t- test for paired data. The elimination rate constant (Ket), the clearance time CI and the apparent volume of distribution (Vd) were significantly (P<0.05) reduced following the second treatment. Ampiclox might have competitively displaced chlorpropamide from the biding site thus giving rise to higher bioavailability and Cmax in the second treatment compared with treatment. The effect of higher bioavaibility and Cmax followinj-the second treatment can be observed by the significant (P<0.05) reduction in the plasma glucose level following the second treatment compared with the first. Co administration of ampiclox with, the long acting chlorpropamide may also affect the renal tubular secretion of the later drug thus slowing down its tubular secretion which can lead to reduced Clearance rate. Thus, the second treatment resulted in increased bioavailability of chlorpropamide with longer half - life of elimination. | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/230 | |
| dc.language.iso | en | en_US |
| dc.subject | INFLUENCE, | en_US |
| dc.subject | AMPICILLIN/CLOXACILLIN, | en_US |
| dc.subject | PHARMACOKINETICS, | en_US |
| dc.subject | CHLORPROPAMIDE, | en_US |
| dc.subject | DIABETES, | en_US |
| dc.subject | MELLITUS PATIENTS | en_US |
| dc.title | INFLUENCE OF AMPICILLIN/CLOXACILLIN ON THE PHARMACOKINETICS OF CHLORPROPAMIDE IN TYPE II DIABETES MELLITUS PATIENTS | en_US |
| dc.type | Thesis | en_US |